Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), will share 8 presentations, including four oral presentations, demonstrating the strength of its Yescarta (axicabtagene ciloleucel) CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).
Positive Survival Outcomes with Yescarta®
Key presentations for Yescarta (axicabtagene ciloleucel) include a five-year follow-up analysis from ZUMA-5 evaluating response rate and long-term survival in patients with R/R indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma. Additionally, Yescarta is the only treatment to have demonstrated superior overall survival versus standard therapy for patients with early R/R large B-cell lymphoma (LBCL), and this continues to be seen in the largest real-world analysis of patients with R/R LBCL who received second-line Yescarta. Additional research will focus on improvements in Yescarta manufacturing for patients with R/R LBCL.
|
Oral Presentations |
|
|
Abstract #526 Sunday, December 8, 2024 10:15 AM Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26 |
Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) |
|
Abstract #527 Sunday, December 8, 2024 10:30 AM Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26 |
Real-world Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-cell Lymphoma (LBCL) in the US: a CIBMTR Report |
|
Abstract #609 Sunday, December 8, 2024 12:30 PM Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4 |
Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) |
|
Abstract #864 Monday, December 9, 2024 4:00 PM Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
|
5-Year Follow-Up Analysis From ZUMA-5: a Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma |
|
Poster Presentations |
|
|
Abstract #2367 Saturday, December 7, 2024 5:30 PM - 7:30 PM San Diego Convention Center, Halls G-H |
Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort |
|
Abstract #3347 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H |
Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma |
|
Abstract #4368 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H |
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel |
|
Abstract #5037 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H
|
Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany |